ck18 primary antibody  (Proteintech)

Journal: Frontiers in Bioengineering and Biotechnology

Article Title: Effects of low-serum adaptation on growth and protein expression in stably lactoferrin-overexpressing mammary alveolar cells

doi: 10.3389/fbioe.2026.1731548

Figure Lengend Snippet: Immunofluorescence images of MAC-T cells. (A) Nucleus staining of MAC-T cells; (B) Cytokeratin 18 (CK18) staining; (C) Combined nucleus and CK18 staining. KSR: Knockout™ serum replacement. ITS: insulin–transferrin–selenium. Scale bar = 200 μm.

Article Snippet: After washed with pre-cooled PBS for 5 min, cells were fixed with 4% paraformaldehyde for 20 min, permeabilized with 0.1% Triton-X-100 for 1 h, and blocked with 5% BSA at room temperature for 2 h. Then primary antibody CK18 (Bioss, bs2043R) diluted at 1:100 was added, followed by overnight incubation at 4 °C and incubation with a fluorescent secondary antibody (Proteintech, RGAR004) at 1:500 dilution in the dark for 2 h. The cells were washed thrice with PBS and stained with DAPI (Beyotime, C1106) ( ).

Techniques: Immunofluorescence, Staining, Knock-Out

Journal: The Journal of Obstetrics and Gynaecology Research

Article Title: Menstrual blood‐derived mesenchymal stem cells combining with platelet‐rich plasma infusion in endometrium repair

doi: 10.1111/jog.16135

Figure Lengend Snippet: MenSCs + PRP significantly induced the protein expression of CK18, vimentin, and ItgαVβ3 in endometrium. The expressions of CK18 (a), vimentin (b), and ItgαVβ3 (c) were observed using IHC staining (red arrows indicate the positive areas in the immunostaining images), and the average optical density was measured using ImageJ software (d–f). The expressions of CK18, vimentin, and ItgαVβ3 were significantly decreased after ethanol perfusion. MenSCs, PRP, and MenSCs + PRP treatment enhanced CK18, vimentin, and ItgαVβ3 expressions, with MenSCs + PRP showing the most significant effects ( n = 3, # p < 0.05, ## p < 0.01, ### p < 0.001, #### p < 0.0001 vs. control; * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 vs. model; & p < 0.05, && p < 0.01, &&& p < 0.001, &&&& p < 0.0001 vs. MenSCs + PRP).

Article Snippet: Chloral hydrate (C104202, Shanghai Aladdin Biochemical Technology Co., Ltd); 10% neutral formalin (G2161, Beijing Solaibao Technology Co., Ltd); DMEM/F12 (11320033, Gibco Life Technologies Co., Ltd); αMEM (41061029, Beijing Solarbio Technology Co., Ltd); 1% cyanine/streptomycin (15070063, Beijing Solarbio Technology Co., Ltd); 0.25% trypsin (25200072, Beijing Solarbio Technology Co., Ltd); CK18 primary antibody (66187‐1‐Ig, Proteintech Technology Co., Ltd); vimentin primary antibody (A19607, Wuhan ABclonal Co., Ltd); ItgαVβ3 primary antibody (abs136335, Shanghai absin Co., Ltd); VEGF primary antibody (abs131208, Shanghai absin Co., Ltd); Goat Anti‐Mouse IgG (A21010, Beijing Abbkine Co., Ltd); Goat Anti‐Rabbit IgG (A23240, Beijing Abbkine Co., Ltd), BSA kits (062122220830, Beyotime Biotechnology).

Techniques: Expressing, Immunohistochemistry, Immunostaining, Software, Control

Journal: The Journal of Obstetrics and Gynaecology Research

Article Title: Menstrual blood‐derived mesenchymal stem cells combining with platelet‐rich plasma infusion in endometrium repair

doi: 10.1111/jog.16135

Figure Lengend Snippet: MenSCs + PRP significantly increased vimentin, CK18, and VEGF expressions in endometrium. The protein expressions in endometrium tissues were determined using WB assay. The vimentin (a), CK18 (b), and VEGF (c) levels were all markedly decreased after modeling, while were significantly increased by MenSCs + PRP, MenSCs, and PRP treatments, with MenSCs + PRP showing the most significant effects ( n = 3, # p < 0.05, ## p < 0.01, ### p < 0.001, #### p < 0.0001 vs. control; * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 vs. model; & p < 0.05, && p < 0.01, &&& p < 0.001, &&&& p < 0.0001 vs. MenSCs + PRP).

Article Snippet: Chloral hydrate (C104202, Shanghai Aladdin Biochemical Technology Co., Ltd); 10% neutral formalin (G2161, Beijing Solaibao Technology Co., Ltd); DMEM/F12 (11320033, Gibco Life Technologies Co., Ltd); αMEM (41061029, Beijing Solarbio Technology Co., Ltd); 1% cyanine/streptomycin (15070063, Beijing Solarbio Technology Co., Ltd); 0.25% trypsin (25200072, Beijing Solarbio Technology Co., Ltd); CK18 primary antibody (66187‐1‐Ig, Proteintech Technology Co., Ltd); vimentin primary antibody (A19607, Wuhan ABclonal Co., Ltd); ItgαVβ3 primary antibody (abs136335, Shanghai absin Co., Ltd); VEGF primary antibody (abs131208, Shanghai absin Co., Ltd); Goat Anti‐Mouse IgG (A21010, Beijing Abbkine Co., Ltd); Goat Anti‐Rabbit IgG (A23240, Beijing Abbkine Co., Ltd), BSA kits (062122220830, Beyotime Biotechnology).

Techniques: Control

Journal: Stem Cell Research & Therapy

Article Title: Prostatic lineage differentiation from human embryonic stem cells through inducible expression of NKX3-1

doi: 10.1186/s13287-024-03886-y

Figure Lengend Snippet: The formation of structural prostate organoids through 3D culture of ESC-derived UGS cells. ( A ) Illustration of the generation of prostatic organoids from human ESCs. ( B ) Brightfield images of organoids at week 1, 2, 3, and 5. Scale bar, 50 μm. ( C ) Diameter statistical graph of organoids after 3D cultivation for the first 20 days. ( D ) DAPI immunofluorescence results of organoids on week 3 and 5. Scale bar, 50 μm. ( E ) Immunofluorescence results of NKX3-1, KI67, FOXA1, and AR on week 3 of organoids cultivation. Scale bar, 50 μm. ( F - I ) H&E staining images ( F ), immunofluorescence results of E-Cadherin ( G ), P63 and CK18 ( H ), and CK5 and CK18 ( I ) of organoids at week 4. Scale bar, 50 μm. ( J ) Flow cytometry results of CK18 of organoids. 3D cultured organoids for 9 days were used (ISO: isotype control)

Article Snippet: The method for cells isolated from prostate organoids is the same as above by using CK5 primary antibody (1:200, Servicebio, #GB111246-50), CK18 primary antibody (1:200, Servicebio, #GB12232-50), CY5-DoαMs secondary antibody (1:200, Jackson Immuno Research, #711-175-151) and FITC-DoαRb secondary antibody (1:200, Jackson Immuno Research, #711-095-152).

Techniques: Derivative Assay, Immunofluorescence, Staining, Flow Cytometry, Cell Culture, Control